Journal article

Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study

Mansi Bhurani, Lorenz Admojo, Carrie Van der Weyden, Robert Twigger, Ali Bazargan, Hang Quach, Allan Zimet, Luke Coyle, Julian Lindsay, Dejan Radeski, Eliza Hawkes, Glen Kennedy, Ian Irving, Naadir Gutta, Judith Trotman, James Yeung, Lindsay Dunlop, Minh Hua, Pratyush Giri, Sam Yuen Show all

Leukemia & Lymphoma | TAYLOR & FRANCIS LTD | Published : 2020


We present a retrospective multicenter study of pralatrexate treatment outcomes in an Australian practice setting for patients with relapsed/refractory T-cell lymphoma who had failed 1+ systemic therapies, treated via a compassionate access program. Endpoints assessed included response rates, toxicities, and subsequent therapies. Progression-free survival (PFS), time to next treatment (TTNT), event-free survival (EFS), overall survival (OS), and time to best response, were assessed by Kaplan-Meier analysis. The study included 31 patients, with median age 69 years. We demonstrated ORR of 35.5% (n = 11), including 4 complete responses (13%) and 7 partial responses (23%). The predicted median O..

View full abstract